Hair Loss Treatments, Inflammation, and New Therapies: GLP-1s, Minoxidil, JAK Inhibitors, and Emerging Topicals

Conclusions

• GLP-1 receptor agonists appear to affect hair in opposite ways: they may directly support follicle growth and reduce inflammation, but rapid weight loss and nutritional stress can trigger telogen effluvium and shedding.
• The most plausible explanation for many hair changes seen with GLP-1 therapy is not a direct toxic effect on hair but systemic metabolic improvement versus rapid catabolic weight loss, with women and faster weight loss showing more shedding.
• Obesity and metabolic inflammation seem to worsen hair disorders, so improving insulin resistance and inflammatory burden may benefit some inflammatory alopecias and scalp disease.
• GLP-1–based therapies may help certain inflammatory hair conditions such as scalp psoriasis, folliculitis decalvans, and some scarring alopecias, but evidence is still early and mostly case-based.
• Minoxidil may have anti-inflammatory effects in addition to hair growth promotion, and long-term use may be useful in inflammatory alopecias rather than being limited to simple cosmetic regrowth.
• Oral minoxidil’s main practical limitation is cardiovascular and edema-related side effects from early peak levels, which extended-release formulations aim to reduce while preserving hair benefit.
• JAK inhibitors remain the strongest current option for alopecia areata, with good efficacy, generally acceptable tolerability, and the best responses when started earlier in the disease course.
• Alopecia areata treatment response seems to depend more on the duration of the current episode than on lifetime disease history, supporting early intervention.
• JAK inhibitors are not a one-time cure; many patients lose gains after stopping therapy, so long-term maintenance treatment is often necessary.
• The major JAK inhibitor safety concerns are serious infection, herpes zoster, malignancy, cardiovascular events, and thrombosis, so patient selection and specialist input matter.
• JAK inhibitors may also have a role in selected scarring alopecias and possibly in oncology-adjunct settings, but they are not established treatments for androgenetic alopecia.
• IL-13–targeting biologics may be useful in patients with atopic dermatitis and hair loss, especially children or patients who cannot take JAK inhibitors, but they can also occasionally be associated with new alopecia areata.
• Atopy and allergy are important comorbidities in alopecia areata and frontal fibrosing alopecia, and allergic triggers, including topical minoxidil and hair products, may matter in some patients.
• Restoring regulatory T-cell balance is an emerging strategy for alopecia areata, and Treg-directed therapies may offer a slower, non-classic-immunosuppressive alternative to JAK inhibitors.
• New topical regenerative approaches such as PP405 are promising because they aim to reactivate dormant follicle stem cells, but the current clinical data are still early and probably premature for broad claims.